Stay updated with breaking news from Clinical Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer. “Salim brings a wealth of relevant experience to Oncternal during this exciting time as we begin to advance our pipeline toward the registrational phase,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We believe that his extensive background in oncology drug develo...
Article content TORONTO — NexJ Health Inc. (NexJ Health), a provider of advanced virtual care solutions for chronic disease prevention and management, is pleased to announce the encouraging results of a Randomized Controlled Trial (RCT) using NexJ Connected Wellness. The study evaluated online mindfulness-based Cognitive Behavioural Therapy (CBT-M) for young adults with major depressive disorder (MDD). The intervention demonstrated large improvements, especially in severely depressed participants. Altogether, there was a 60% remission rate in individuals who received the intervention. Of ...
The faculty and staff at the Texas Tech School of Veterinary Medicine now know who will be in their inaugural class. There was a specific mission in mind when deciding who the admissions committee would offer the opportunity to study at the Tech School of Veterinary Medicine. Dr. John Dascanio is a theriogenology professor and is the senior associate dean for Academic and Student Services at the Tech School of Veterinary Medicine. Dascanio discussed the mission that was kept in mind for what the admissions committee was looking for. âWe had a very unique admissions process that was tied ...
Published: Apr 19, 2021 BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020. "2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the ...